Lancet: Chemo w/ docetaxel improves survival

Links shared publicly online about this topic.

586
total visits

Lancet: Chemo w/ docetaxel improves survival

The addition of docetaxel to an induction chemotherapy regiment in patients with locally advanced head and neck cancer improved five-year survival rates from 42 percent to 52 percent and nearly doubled median survival time, leading researchers to recommend the three-drug regiment for eligible patients, with the findings published Jan. 12 in The Lancet Oncology.

View full resource at healthimaging.com

Tags: Cancer, Cancer Medication, Chemotherapy, Head and Neck Cancer, Taxotere, Oncology